Bayer is pouring $2.2 billion into a new pharmaceutical manufacturing campus in New Albany, with the project expected to create about 600 high-value jobs and roughly 1,500 construction roles before the first phase even opens. The flexible, modular facility will rise inside the New Albany International Business Park, adding a major new player to central Ohio's fast-growing life sciences corridor.
A Modular Campus Built in Phases
According to businesswire.com, the project is designed as a flexible, modular campus that combines drug-substance and drug-product manufacturing on the same site. The first module, focused on drug-substance manufacturing, is expected to become operational in 2031, with a second module dedicated to drug-product manufacturing following in 2034. Bayer says the facility will use advanced digital and automation technologies as it ramps up production, according to WOSU.
The campus will initially support Bayer's portfolio in oncology, cardiovascular care and renal care, meaning the medicines produced there are aimed at treating cancer, heart conditions and kidney disease, per WSYX. The New Albany site will complement Bayer's U.S. pharmaceuticals headquarters in Whippany, New Jersey, and the company's other U.S. sites, the station reports.
Why Ohio Over Everywhere Else
Governor Mike DeWine framed the decision as a statement about the state's standing in the industry, saying Bayer could have built the facility anywhere in the United States but chose Ohio, which he described as evidence of the state's growing reputation as a destination for life sciences investment, according to WSYX. JobsOhio president and CEO J.P. Nauseef put it more bluntly, saying Bayer chose a workforce as well as a site, the outlet reports.
Ohio beat out other competitors for the project, with the state citing best-in-class infrastructure and shovel-ready land as deciding factors, per WSYX. The New Albany area already hosts a life sciences cluster that includes Amgen, Hims & Hers, American Regent and Pharmavite, giving Bayer an established ecosystem of neighbors rather than a blank slate.
Public Money and Pending Incentives
Bayer is pursuing a Job Creation Tax Credit from the Ohio Department of Development and will seek assistance from JobsOhio, though the companies involved say more details will be released once agreements are finalized, per the same WOSU report. The investment adds to more than $7 billion Bayer has spent on U.S. pharmaceutical research, development and manufacturing over the past five years, according to businesswire.com.
The project arrives alongside a broader state push to build out the talent pipeline for jobs like these. Ohio's Life Science Training Center, under construction in the New Albany International Business Park, is scheduled to open in summer 2027 and will prepare Ohioans for biomanufacturing operator and technician roles, per WOSU's report. JobsOhio, the city of New Albany and The New Albany Company are investing more than $30 million in that training center, with additional funding expected from the state and private partners.
A Workforce Already Growing Fast
The timing lines up with a statewide employment shift: pharmaceutical and medicine manufacturing employment grew 24% from 2015 to 2024, and technical and skills-based roles now make up 42% of biopharmaceutical manufacturing employment, according to Ohio Tech News. The life sciences industry already employs 18,000 people in central Ohio and 64,000 statewide, per JobsOhio. The training center is intended to prepare students for entry-level operator roles in biopharmaceutical manufacturing, according to GEN.
What Local and National Leaders Are Saying
Bayer executive Bill Anderson said the United States remains a key manufacturing base and innovation hub for the company, while Jonas Peterson, chief economic development officer and president of One Columbus, said the decision reflects the Columbus region's growing position as a global life sciences center, both according to WSYX. Congresswoman Joyce Beatty said the investment will bring 600 new jobs and more opportunities for central Ohio families, and New Albany officials including Sloan Spalding said the project builds on local and statewide momentum, the station reports.
Bayer says the New Albany campus will help deliver innovative, high-quality medicines to patients in the United States and overseas, and is expected to form a collaboration ecosystem linking academic innovation with manufacturing expertise. Elsewhere in the pharmaceutical sector, Pennsylvania has pursued its own large-scale manufacturing win, with the state investing $100 million to support a Lilly project in the Lehigh Valley expected to create 850 jobs, according to the Pennsylvania Department of Community and Economic Development, underscoring how aggressively states are now competing for this kind of investment.
